<?xml version='1.0' encoding='utf-8'?>
<document id="25725071"><sentence text="GW4064, an agonist of farnesoid X receptor, represses CYP3A4 expression in human hepatocytes by inducing small heterodimer partner expression." /><sentence text="Farnesoid X receptor (FXR) functions as a regulator of bile acid and lipid homeostasis and is recognized as a promising therapeutic target for metabolic diseases" /><sentence text=" The biologic function of FXR is mediated in part by a small heterodimer partner (SHP); ligand-activated FXR enhances SHP expression, and SHP in turn represses the activity of multiple transcription factors" /><sentence text=" This study aimed to investigate the effect of FXR activation on expression of the major drug-metabolizing enzyme CYP3A4" /><sentence text=" The effects of 3-(2,6-dichlorophenyl)-4-(3'-carboxy-2-chlorostilben-4-yl)oxymethyl-5-isopropylisoxazole (GW4064), a synthetic agonist of FXR, on the expression and activity of CYP3A4 were examined in primary human hepatocytes by using quantitative real-time polymerase chain reaction and S9 phenotyping"><entity charOffset="16-104" id="DDI-PubMed.25725071.s5.e0" text="3-(2,6-dichlorophenyl)-4-(3'-carboxy-2-chlorostilben-4-yl)oxymethyl-5-isopropylisoxazole" /><entity charOffset="106-112" id="DDI-PubMed.25725071.s5.e1" text="GW4064" /><pair ddi="false" e1="DDI-PubMed.25725071.s5.e0" e2="DDI-PubMed.25725071.s5.e0" /><pair ddi="false" e1="DDI-PubMed.25725071.s5.e0" e2="DDI-PubMed.25725071.s5.e1" /></sentence><sentence text=" In human hepatocytes, treatment of GW4064 (1 μM) for 48 hours resulted in a 75% decrease in CYP3A4 mRNA expression and a 25% decrease in CYP3A4 activity, accompanied by ∼3-fold increase in SHP mRNA expression" /><sentence text=" In HepG2 cells, SHP repressed transactivation of CYP3A4 promoter by pregnane X receptor (PXR), constitutive androstane receptor (CAR), and glucocorticoid receptor"><entity charOffset="109-119" id="DDI-PubMed.25725071.s7.e0" text="androstane" /><entity charOffset="140-154" id="DDI-PubMed.25725071.s7.e1" text="glucocorticoid" /><pair ddi="false" e1="DDI-PubMed.25725071.s7.e0" e2="DDI-PubMed.25725071.s7.e0" /><pair ddi="false" e1="DDI-PubMed.25725071.s7.e0" e2="DDI-PubMed.25725071.s7.e1" /></sentence><sentence text=" Interestingly, GW4064 did not repress expression of CYP2B6, another target gene of PXR and CAR; GW4064 enhanced CYP2B6 promoter activity" /><sentence text=" In conclusion, GW4064 represses CYP3A4 expression in human hepatocytes, potentially through upregulation of SHP expression and subsequent repression of CYP3A4 promoter activity" /><sentence text=" Clinically significant drug-drug interaction involving FXR agonists and CYP3A4 substrates may occur" /><sentence text=" " /></document>